Literature DB >> 9285420

MR differentiation of phaeochromocytoma from other adrenal lesions based on qualitative analysis of T2 relaxation times.

J C Varghese1, P F Hahn, N Papanicolaou, W W Mayo-Smith, J A Gaa, M J Lee.   

Abstract

AIM: To determine the diagnostic accuracy of MR imaging in differentiating phaeochromocytoma from other adrenal lesions.
MATERIALS AND METHODS: Sixty-seven adrenal masses (65 patients) including 17 phaeochromocytomas were imaged using T2-weighted pulse sequences on 0.6 T and 1.5 T GE MR units. The adrenal lesions were qualitatively assessed by three observers and divided into three categories (benign adenomas, malignant lesions and phaeochromocytomas) based on lesion signal intensity relative to liver and cerebrospinal fluid.
RESULTS: Eleven phaeochromocytomas (65%) were correctly identified while the remaining six (35%) were misclassified, five as malignant lesions and one as a benign adenoma, because of atypical low signal intensity on T2-weighted MR images. Conversely, six non-phaeochromocytomas (three benign adenomas, two adrenal carcinomas and one metastasis) were wrongly classified as phaeochromocytomas because of very high lesion signal intensity. The sensitivity of MR imaging for diagnosing phaeochromocytoma was 64.7%, specificity 88.0%, positive predictive value 64.7% and negative predictive value 88.0%.
CONCLUSION: There is considerable overlap between the MR appearance of phaeochromocytoma and other adrenal lesions. A phaeochromocytoma cannot be excluded on the basis of a lack of high signal intensity on T2-weighted MR imaging.

Entities:  

Mesh:

Year:  1997        PMID: 9285420     DOI: 10.1016/s0009-9260(97)80252-8

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  18 in total

1.  Images of pheochromocytoma in adrenal glands.

Authors:  Shaunagh McDermott; Colin J McCarthy; Michael A Blake
Journal:  Gland Surg       Date:  2015-08

Review 2.  Imaging of pheochromocytoma and paraganglioma.

Authors:  I Brink; S Hoegerle; J Klisch; T A Bley
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

Review 3.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

4.  Utility of T2-weighted MRI to Differentiate Adrenal Metastases from Lipid-Poor Adrenal Adenomas.

Authors:  Wendy Tu; Jorge Abreu-Gomez; Amar Udare; Abdulmohsen Alrashed; Nicola Schieda
Journal:  Radiol Imaging Cancer       Date:  2020-10-30

5.  Comparison of MRI features in lipid-rich and lipid-poor adrenal adenomas using subjective and quantitative analysis.

Authors:  Wendy Tu; Rosalind Gerson; Jorge Abreu-Gomez; Amar Udare; Rachel Mcphedran; Nicola Schieda
Journal:  Abdom Radiol (NY)       Date:  2021-06-12

Review 6.  Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma.

Authors:  David Taïeb; Karel Pacak
Journal:  Cell Tissue Res       Date:  2018-02-15       Impact factor: 5.249

7.  Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function.

Authors:  Audrey E T Jacques; Anju Sahdev; Madrika Sandrasagara; Rick Goldstein; Daniel Berney; Andrea G Rockall; Shern Chew; Rodney H Reznek
Journal:  Eur Radiol       Date:  2008-07-19       Impact factor: 5.315

8.  An organ of Zuckerkandl tumour shown by MRA (2007: 12b).

Authors:  Katerina Lekanidi; Panos Koumellis; Peter Bungay; James D Birchall
Journal:  Eur Radiol       Date:  2008-02-09       Impact factor: 5.315

9.  Myxoid adrenocortical adenoma: magnetic resonance imaging and pathology correlation.

Authors:  Tae Un Kim; Suk Kim; Jun Woo Lee; Nam Kyung Lee; Hong Koo Ha; Won Young Park
Journal:  Korean J Radiol       Date:  2014-03-07       Impact factor: 3.500

10.  Pheochromocytoma in Urologic Practice.

Authors:  Nikhil Waingankar; Gennady Bratslavsky; Camilo Jimenez; Paul Russo; Alexander Kutikov
Journal:  Eur Urol Focus       Date:  2016-09-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.